US Patent

US11191766 — Methods of treating pediatric cancers

Method of Use · Assigned to Loxo Oncology Inc · Expires 2037-04-04 · 11y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating pediatric cancer by administering a therapeutically effective amount of Larotrectinib sulfate or a related compound.

USPTO Abstract

A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)âN-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2471`	—	larotrectinib-sulfate

Patent Metadata

Patent number: US11191766
Jurisdiction: US
Classification: Method of Use
Expires: 2037-04-04
Drug substance claim: No
Drug product claim: No
Assignee: Loxo Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.